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Abstract
Background:  Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable
hematologic toxicity profile. Its active drug, doxorubicin, has interesting immunomodulatory properties.
Here, the effects of Doxil on surviving tumor cell immunophenotype were investigated.
Methods: Using ID8 murine ovarian cancer cells, the immunomodulatory effects of Doxil were studied
by measuring its impact on ovarian cancer cell expression of MHC class-I and Fas, and susceptibility to
immune attack in vitro. To evaluate the ability of Doxil to cooperate with cancer immunotherapy, the
interaction between Doxil and Interleukin 18 (IL-18), a pleiotropic immunostimulatory cytokine, was
investigated in vivo in mice bearing ID8-Vegf tumors.
Results: While Doxil killed ID8 tumor cells in a dose-dependent manner, tumor cells escaping Doxil-
induced apoptosis upregulated surface expression of MHC-I and Fas, and were sensitized to CTL killing
and Fas-mediated death in vitro. We therefore tested the hypothesis that the combination of
immunotherapy with Doxil provides positive interactions. Combination IL-18 and Doxil significantly
suppressed tumor growth compared with either monotherapy in vivo and uniquely resulted in complete
tumor regression and long term antitumor protection in a significant proportion of mice.
Conclusion: These data demonstrate that Doxil favorably changes the immunophenotype of a large
fraction of the tumor that escapes direct killing thus creating an opportunity to expand tumor killing by
immunotherapy, which can be capitalized through addition of IL-18 in vivo.
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Background
Successful cancer chemotherapy relies on the comprehen-
sive tumor cell elimination. However, at clinically toler-
ated doses, chemotherapeutic drugs usually fail to kill all
tumor cells in vivo. Theoretically, to achieve complete
eradication, partial tumor killing by chemotherapy
should be accompanied by a "bystander effect" in which
the immune system recognizes, attacks, and eradicates
residual tumor cells. Unfortunately, most cytotoxic anti-
cancer agents used in the clinic exert immunosuppressive
side effects.
Doxorubicin (or adriamycin) is an anthracycline antibi-
otic that intercalates with DNA, inhibiting its replication.
Pegylated liposomal doxorubicin (Doxil) extravasates
efficiently through the leaky tumor vasculature and is pro-
tected from renal clearance, enzymatic degradation, and
immune recognition, enhancing drug pharmacokinetics,
reducing hematologic effects and achieving targeted deliv-
ery to the tumor site. Unlike other chemotherapeutic
agents, Doxorubicin possesses interesting immunomodu-
latory properties, potentiating Her-2 cancer vaccination in
mice [1] and inducing immunogenic tumor cell apoptosis
[2,3]. Tumors are however known to escape immune
attack through downregulation of surface molecules that
mediate antigen presentation and immune recognition,
such as major histocompatibility complex (MHC) mole-
cules, and modulating death receptors and other immu-
nomodulatory ligands. Accordingly, investigation is
required to elucidate mechanisms that both increase the
immunogenicity of tumor cells surviving chemotherapy
and boost effector immune mechanisms.
Immunostimulatory cytokine therapy may be an attrac-
tive approach to capitalize on the immune effects of dox-
orubicin. Doxorubicin has been shown to enhance the
therapeutic effect of TNF-α, IL-2 and IL-12 in mouse mod-
els of cancer [4-6]. Interleukin-18 (IL-18) has now
emerged as a novel cytokine with potent immunostimula-
tory properties which affects multiple subpopulations of
immune cells of the adaptive and innate immune system.
It activates effector T cells; induces IFN-γ, TNF-α, IL-1α,
and GM-CSF production; promotes Th1 differentiation of
naive T cells; and augments natural killer (NK) cell cyto-
toxicity [7-10]. IL-18 promotes protection against tumor
challenge in mice [7]. In phase I evaluation, recombinant
human (rh)IL-18 monotherapy has been safely adminis-
tered to 28 patients with solid tumors, with two partial
tumor responses [9]. Compared with other immunostim-
ulatory cytokines, its toxicity profile is remarkable; mild to
moderate toxicities even with repeat administration and a
maximum tolerated dose that has not been reached [11].
IL-18 enhanced activation of peripheral blood CD8+ T
cells, NK cells and monocytes and induced a transient
increase in Fas ligand (FasL) by circulating CD8+ T cells
and NK cells [11].
We hypothesized that IL-18 a well suited drug for combi-
natorial therapies with pegylated Doxil to enhance clini-
cal efficacy. Doxil has become standard second line drug
for the treatment of patients with platinum refractory or
resistant disease ovarian cancer. Importantly, cell-medi-
ated immune mechanisms appear to play a role in con-
trolling progression of ovarian carcinoma [12] and early
phase clinical results suggest that the use of immuno-
therapy can provide clinical benefit in ovarian cancer [13].
Because the effect of immune therapy becomes clinically
relevant only if immune mechanisms target the tumor
fraction surviving chemotherapy, we studied the fate of
tumor cells escaping direct killing by Doxil. We hypothe-
sized that tumor surviving Doxil chemotherapy becomes
sensitized to cytotoxic lymphocytes and can be effectively
targeted by the immune response activated by IL-18, pro-
viding the basis for positive therapeutic interactions.
Materials and methods
Cell culture
ID8 ovarian cancer cells were donated by Drs. Kathy
Robby and Paul Terranova (Kansas University)[14]. ID8-
Vegf and ID8-E6E7 cell lines were described elsewhere
[15,16]. ID8, ID8-E6E7 and ID8-Vegf cells were main-
tained in DMEM media (Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 μg/ml streptomycin (Roche, Indiana-
polis, IN) in 5% CO2 at 37°C.
Mice
Eight week old female C57BL/6 mice (Charles River Lab-
oratories, Wilmington, MA) were used in protocols
approved by the Institutional Review Board of the Univer-
sity of Pennsylvania.
Tumor inoculation
For intraperitoneal (i.p.) tumors, ID8-Vegf cells were
injected at 5 × 106 per mouse. For subcutaneous (s.c.)
tumors, a single cell suspension of ID8-Vegf cells was pre-
pared in phosphate buffered saline (PBS) mixed with an
equal volume of cold Matrigel. 107 cells in 0.5 ml total
volume was injected into the flank. Tumors were detecta-
ble two weeks later. Tumor size was measured weekly
using a Vernier caliper. Tumor volumes were calculated by
the formula V = 1/2 (L × W)2, where L is length (longest
dimension) and W is width (shortest dimension). When
control tumors reached the size of ~800 mm3, animals
were sacrificed, and tumors excised and weighed.
In Vivo Treatment
Mice were treated with i.p. bolus injections of Doxil in the
range of 17% to 50% of maximally tolerated dose (MTD)Journal of Translational Medicine 2009, 7:104 http://www.translational-medicine.com/content/7/1/104
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for mice [17] or 5% dextrose weekly for 4 weeks. Chemo-
therapy treatment started one week (i.p. model) or 14
days (s.c. model) after tumor inoculation; IL-18 treatment
began 2 days later. IL-18 or 0.9% saline was given s.c. at
10, 30 or 100 μg/mouse, daily for 50 days.
In vitro treatment of tumor cells
ID8 cells were exposed to Doxil at 0, 0.1, 0.3 or 1 μg/ml
concentrations for 6 hours. The cells were washed twice
with PBS, and cultured in drug-free media for another 42
hours. ID8 cells were then washed twice with PBS,
trypsinized and counted. Non-viable cells were excluded
using Trypan Blue staining. Fas-induced killing was medi-
ated by anti-Fas agonistic monoclonal antibody (mAb)
Jo2 (BD PharMingen) crosslinked using Protein G (2 μg/
ml; Biovision) or isotype-matched Ab and protein G. Anti-
body was added 24 hours before cell harvesting and
counting.
Flow cytometry
Cells were blocked and stained with biotinylated anti-
MHC-I (H-2Kb/H-2Db) mAb with APC-labeled Streptavi-
din, PE-labeled anti-Fas mAb or isotype-matched controls
(BD PharMingen, San Diego, CA). Apoptosis was meas-
ured using TACS Annexin V-FITC apoptosis detection sys-
tem (R&D Systems; Minneapolis, MN). Analysis was
performed using a FACS Canto cytometer.
Cytotoxicity assay
ID8-E6E7 cells were used as targets in a colorimetric non-
radioactive cytotoxicity assay measuring LDH (Promega).
Target cells (12 × 103 cells/well) were coincubated with T
cells at various E:T cell ratios, in 200 μl RPMI-10 (RPMI
supplemented with 10% FBS, 100 U/ml Penicillin, and
100 ug/ml Streptomycin) for 4 hrs at 37°C in 5% CO2.
Effector cells were from eight to sixteen-week old C57BL/
6 mice vaccinated twice, one week apart, with DNA plas-
mid vaccine encoding the E7 peptide and Listeriolysin O
as an adjuvant, kindly provided by Dr. Yvonne Paterson.
One month later, mice were inoculated s.c. in the flank
with 50,000 E7 expressing TC-1 cells. Two weeks later
mice were sacrificed; splenocytes isolated; and stimulated
in vitro for 7 days with 8 μg/ml E7 peptide and 30 IU/ml
IL-2 in RPMI-10. % specific cytotoxicity = (experimental -
spontaneous/maximum - spontaneous) × 100.
Statistical analysis
Two-tailed Student's t-test was used for between-group
comparisons with in vitro and flow cytometry data. Differ-
ences between treatment groups were considered signifi-
cant at the level of p < 0.05. Kaplan-Meier survival curves
were computed. A Cox regression model was used to
obtain the hazard ratios (HR) for each treatment group
compared to the control group and their 95% confidence
intervals.
Results
Doxil treatment favorably alters cancer cell 
immunophenotype in vitro
Cell damage induced by chemotherapy can sensitize
tumor to immune effector cells [18]. To assess the capacity
of Doxil to sensitize ovarian cancer cells to immune
attack, we identified doses of Doxil in vitro at which
greater than 50% of ID8 cells remained viable (Figure 1A).
ID8 cells were exposed to Doxil for 6 hours, washed and
incubated for an additional 42 hours in drug-free media.
At concentrations ≤ 0.3 ug/ml, Doxil reproducibly yielded
cell cultures with cell viability > 50% (Figure 1A). Treated
ID8 cells were harvested and analyzed for cell surface phe-
notype by flow cytometry. Doxil induced a significant,
dose-dependent upregulation of MHC-I and Fas in ID8
tumor cells (Figure 1B). There was no significant increase
in the expression of MHC-II, the NKG2D ligands RaeI and
H60 or death receptors 4 (DR4) and DR5 in ID8 cells fol-
lowing exposure to Doxil (data not shown).
Chemotherapeutic agents can promote MHC-I or NKG2D
ligand upregulation by tumor cells and to sensitize them
to Fas or TRAIL mediated apoptosis [19,20], but it is
unclear whether this occurs mainly in tumor cells des-
tined to die from chemotherapy-induced cytotoxicity or
the fraction of cells surviving the chemotherapeutic insult.
We found that Doxil induced a significantly upregulated
MHC-I and Fas in non-apoptotic (Annexin V-negative)
ID8 tumor cells (Figure 1C). At the 1 μg/mL Doxil concen-
tration, the majority (> 75%) of the non-apoptotic cells
upregulated MHC-I, compared to less than 10% in the
untreated group. Fas expression was detectable at an inter-
mediate level in untreated cells, but was expressed at high
levels on all ID8 viable cells at both 0.1 and 1 μg/mL
Doxil concentrations, with higher expression levels at the
increased drug concentration.
Doxil treated cancer cell are more susceptible to immune 
attack
Increased expression of immune-associated molecules by
viable ID8 cells following Doxil exposure suggested their
elevated susceptibility to immune recognition and killing.
To test this hypothesis, ID8-E6/E7 cells, expressing
human papilloma virus E6 and E7 as surrogate tumor
antigens [16], were exposed to Doxil for 6 hrs at 1 μg/ml.
(Figure 2A). Forty-two hrs later, the majority of viable
ID8-E6/E7 tumor cells co-expressed MHC-I and Fas, simi-
lar to the ID8 control line (Figure 2A). E7-reactive CD8
effector T cells harvested from E7-vaccinated mice and
stimulated in vitro using synthetic E7 peptide were coincu-
bated with ID8-E6/E7 and control ID8 target cells that
had been exposed to Doxil for 6 hrs. Doxil exposure
increased the susceptibility of ID8-E6/E7 target cells to T
cell-mediated lysis at a 20:1 ratio compared to untreated
ID8-E6/E7 controls (Figure 2B) or control ID8 cells (notJournal of Translational Medicine 2009, 7:104 http://www.translational-medicine.com/content/7/1/104
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shown). To evaluate the susceptibility of ID8 cancer cells
surviving Doxil to Fas-mediated cell death, Doxil-treated
and untreated ID8 cells were incubated with Fas agonistic
antibody or with isotype matched antibody for 24 hours,
and measured for viability. ID8 cells exposed to Doxil also
showed increased sensitivity to Fas agonistic antibody
(two-tailed t-Test; p = 0.002; Figure 2C).
Positive interaction between Doxil and IL-18 
immunotherapy in vivo
Sensitization of ID8 tumor cells by Doxil to cytotoxic T
cell-mediated lysis suggested that immunostimulatory
cytokine therapy could effectively target chemotherapy-
surviving cancer cells and in combination improve the
efficacy of Doxil therapy. We therefore tested IL-18 and
Doxil combination therapy in C57BL/6 mice inoculated
s.c. with ID8-Vegf tumors. Compared to Doxil mono-
therapy, combinatorial therapy significantly decreased
tumor growth (Figure 3A and 3B). Median tumor weight
and interquartile range was 400 mg (271.5-604) in the
Doxil treatment group and 220 mg (190-280; Student's t-
Test, p = 0.034) in the combinatorial treatment group
(Figure 3A).
Doxil treated ovarian cancer cells upregulate MHC class-I and Fas expression in vitro Figure 1
Doxil treated ovarian cancer cells upregulate MHC class-I and Fas expression in vitro. (A) ID8 cells were exposed 
to titered concentrations of Doxil (0, 0.3, 1 and 3 ug/ml) and measured for viable cell countsmeasured. ID8 cells were either 
incubated in culture media alone or with the indicated concentration of Doxil for 6 hours, washed, and incubated in drug-free 
media for 42 hours before harvesting. (B) Upregulation of MHC-I (left) and Fas (right) on ID8 cells following treatment with 
Doxil and staining with MHC-I and Fas antibodies. Histogram: Isotype control (red); untreated (blue); Doxil 0.1 μg/ml (green); 
Doxil 1 μg/ml (brown). All the histograms depict Annexin-V negative (non apoptotic cells). B) Dot plot diagrams depict the 
upregulation of MHC-I and Fas in gated non-apoptotic (Annexin v-negative) tumor cells exposed to Doxil 42 hours before.
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Both monotherapies and combination therapy signifi-
cantly improved survival compared to the untreated con-
trol group (IL-18 group, p < 0.001; Doxil group, p < 0.001;
log-rank test) (Figure 3C). Median survival was increased
in mice receiving Doxil therapy (with or without IL-18)
compared to IL-18 monotherapy. Median survival was
similar in mice receiving Doxil therapy with or without IL-
18; however tumor cures were only observed in mice
receiving combinatorial therapy. Combination Doxil/IL-
18 therapy resulted in 22% 6-month overall survival com-
pared to 0% for the respective monotherapies (Figure 3C).
All tumor-cured animals were effectively protected from
s.c. re-challenge with ID8-Vegf cells.
To optimize dosing, we combined different doses of Doxil
(2.5, 5 or 7.5 mg/kg) with different doses of IL-18 (10, 30
or 100 μg) and computed Kaplan-Meier survival curves
(Figure 4). Untreated mice died in less than 15 weeks after
tumor inoculation. Compared to the control mice, at the
lowest dose of Doxil (2.5 mg/kg), the most significant
improvement in survival was at the 100 μg dose of IL-18
(HR = 0.13, 95% confidence interval of 0.03-0.57). At the
intermediate Doxil dose of 5 mg/kg, the most significant
improvement in survival was with IL-18 at the intermedi-
ate (30 μg) dose (HR = 0.11, 0.02-0.46). At the highest
Doxil dose (7.5 mg/kg), there was improved survival at all
three doses of IL-18 (HR = 0.11, 0.14, 0.13, respectively).
Increased susceptibility of viable ovarian cancer cells to immune attack after Doxil exposure Figure 2
Increased susceptibility of viable ovarian cancer cells to immune attack after Doxil exposure. (A) Upregulation of 
MHC-I and Fas on ID8-E6E7 cells following treatment with Doxil at 0.1 μg/ml or 1 μg/ml. (B) Left, Increased sensitivity of ID8-
E6E7 cells to CTL activated with IL-2 and E7 peptide. The effector to target ratio (E:T) is indicated. Each data point represents 
the mean of triplicate wells. Experiments repeated twice with similar results. (C) Treatment of ID8 cells with Doxil sensitizes 
them to Fas agonistic antibody (right). The ID8 cells (untreated or treated with Doxil) have been incubated with the Fas agonis-
tic antibody and recombinant protein G or with isotype matched antibody and recombinant protein G for 24 hours. Cells were 
harvested (trypsin), stained with trypan blue and viable cells were counted. The bars show the means and standard error of the 
mean for three independent experiments.
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The combination of Doxil at 5 mg/kg with IL-18 at 30 μg
resulted in a 6-month survival of 40%. A similar level of
survival was obtained with combination Doxil at 2.5 mg/
kg with IL-18 at 100 μg (Figure 4) suggesting that the effi-
cacy of Doxil therapy for ovarian cancer can be improved
by the addition of IL-18.
Discussion
The identification of favorable chemotherapy and
immune therapy combinations remains a critical task for
improving cancer outcomes. Doxil has not been reported
to exhibit T cell suppressive activity to date and its low
hematologic toxicity profile makes it an ideal drug to
combine with immunotherapy. Our findings show that
tumor cells surviving Doxil upregulate surface molecules
that are critical for immune recognition and attack such as
MHC class I and Fas through an unknown mechanism,
and exhibit increased sensitivity to killing by cytotoxic
lymphocytes and to apoptosis mediated by Fas in vitro.
Therefore, in addition to direct tumor killing and the
immunization effect derived from immunogenic cell
death, Doxil exerts an important immunomodulatory
effect upon the tumor fraction surviving drug exposure.
This effect is distinct and complementary to the previously
described effect of adriamycin which was shown to elicit a
vaccination effect by mediating immunogenic death in
tumor cells. Anthracycline-induced immunogenic death is
associated with caspase activation [2] and mediated by
rapid, preapoptotic translocation of calreticulin to the cell
surface, promoting immunogenicity [3]. The effect
observed in our studies is indeed distinct as it affects pri-
marily the non-apoptotic fraction of tumor following
treatment with Doxil.
The combination of IL-18 with Doxil at doses below the
maximally tolerated dose substantially restricted tumor
growth in comparison with Doxil or IL-18 monotherapy.
Improved tumor control by combination therapy is pre-
sumed to be mediated through the amalgamation of IL-18
mediated immune activation, with Doxil-mediated tumo-
ricidal activity and increased immunogenicity of the sur-
viving tumor cell fraction in vivo. Although upregulation
of MHC class I and Fas expression by surviving tumor cells
was not evaluated on tumor biopsies, the combinatorial
therapy produced complete tumor regression and cure in
a substantial number of mice, while no cures were
observed in mice treated with pegylated liposomal doxo-
rubicin or IL-18 monotherapy. Thus, the addition of IL-
18, an immunostimulatory cytokine with an established
safety profile, to standard Doxil chemotherapy may signif-
icantly increase tumor response and lead to increased
tumor elimination.
IL-18 has recently emerged as an immunostimulatory
cytokine with the capacity to augment anticancer therapy.
In mice, IL-18 promotes protection against tumor chal-
Combination therapy for C57BL/6 mice injected in the flank with ID8-Vegf cells Figure 3
Combination therapy for C57BL/6 mice injected in the flank with ID8-Vegf cells. Tumors from mice treated with 
Doxil with or without IL-18 were excised and weighed when the Doxil treated tumors reached the size of 600 mm3. Results 
are medians (50th percentile); error bars: interquartile range (25%-75%), (n = 9). (A) The Doxil-IL-18 combination treatment 
restricts significantly the tumor weight compared to the Doxil treated group (p = 0.034) (upper graph). Doxil was given at 4 
mg/kg/dose for 4 weekly doses starting two weeks after tumor inoculation, while IL-18 was given at 10 μg daily for 50 days 
starting two days later. (B) The picture shows four tumors from mice treated with the combination of IL-18 and Doxil (upper 
row) and four tumors from mice treated with Doxil monotherapy (lower row). (C) The effect of mono- and combination 
therapy on tumor growth in vivo. C57BL/6 mice were injected i.p. with ID8-Vegf cells and subsequently treated. The chemo-
therapy treatment was started one week after the tumor challenge and IL-18 treatment 2 days later. In the Doxil-IL-18 combi-
nation group, 22% of the mice remained tumor-free 6 months after the tumor challenge while in the groups treated with either 
monotherapy the overall 6-month survival was 0% (untreated control: n = 9, IL-18: n = 9, Doxil: n = 8, Combination: n = 9). 
The tumor-free mice were rechallenged with ID8-Vegf cells injected s.c. and the tumors were rejected.
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Combining different doses of Doxil and IL-18 for optimized therapy Figure 4
Combining different doses of Doxil and IL-18 for optimized therapy. (A) Kaplan-Meier survival curves show the 
effects of Doxil therapy at 2.5, 5, or 7.5 mg/Kg when combined with different doses of IL-18 and administered to ID8-Vegf 
tumor bearing mice (n = 5/dose group). Mice received IL-18 doses of 10 (green), 30 (teal), or 100 (blue) ug/mouse, or no IL-18 
as control (red). Mice were treated with i.p. bolus injections of Doxil or 5% dextrose control (black) given weekly for 4 weeks. 
Chemotherapy treatment started one week after i.p. tumor inoculation; IL-18 treatment began 2 days later. IL-18 or 0.9% 
saline was given s.c. at 10, 30 or 100 μg/mouse, daily for 50 days. (B) Improved survival was determined in combination ther-
apy groups using the hazard ratios (HR) for each treatment group compared to the control group and their 95% confidence 
intervals. Combinations of IL-18 and Doxil showing improved survival HR are shaded.
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lenge, and enhances NK cell cytotoxocity and T cell effec-
tor function [7,10]. IL-18 has immunostimulatory effects
on human cells as well. Administration of IL-18 has been
shown to augment adoptive human T cell transfer in a
xenogeneic mouse model of graft versus host disease, by
diminishing the engraftment of regulatory T cells and
enhancing the engraftment of effector T cells and pathol-
ogy in vivo [21]. As a monotherapy, IL-18 achieved lim-
ited clinical efficacy in a phase I study, however, IL-18 did
increase activation molecule expression on circulating T
cells, NK cells and monocytes, and induced a transient
increase in Fas ligand (FasL) expression by circulating
CD8+ T cells and NK cells [9,11]. Earlier reports also sug-
gested a role for IL-18 as an anti-angiogenic inhibitor of
solid tumor outgrowth [22]. Reciprocally, the immunos-
timulatory capacity of IL-18 may promote the aggressive-
ness of myeloid leukemia cells [23]. In ovarian cancer, IL-
18 single nucleotide polymorphism (SNP) analysis does
not reveal evidence for an association with epithelial ovar-
ian cancer risk [24]. However, increased levels of serum
IL-18 has been reported to correlate with advanced dis-
ease, which mechanistically may reflect production by
tumor-stimulated immune cells or by tumor cells them-
selves [25]. Accordingly, the capacity to provide super-
physiological concentrations of IL-18 through passive
cytokine administration provides the opportunity to pro-
mote antitumor responses in patients with ovarian cancer
in vivo.
The observed positive interaction between Doxil and IL-
18 complements previous evidence that adriamycin can
enhance immunotherapy [1,5]. However, in these prior
studies, doxorubicin was administered prior to immuno-
therapy, making it possible that this effect was mediated
by attenuation of immunosuppressive mechanisms. Our
findings are unique in that they report long term co-
administration of chemotherapy with cytokine therapy
and suggest that this positive drug interaction results in
significant expansion of the tumor fraction that is killed
by the combined therapy. The favorable safety profiles of
both IL-18 and Doxil, coupled with the potent therapeutic
effect of their combination reported herein, warrants the
clinical evaluation of this combinatorial approach in
ovarian cancer.
Conclusion
In conclusion, we provide evidence that Doxil favorably
alters the immunophenotype of cancer cells that survive
direct killing allowing for increased tumor killing by IL-18
immunotherapy in vivo.
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